Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.
Milestone Pharmaceuticals Inc. (MIST) is a clinical-stage biopharmaceutical company pioneering patient-administered therapies for cardiovascular emergencies. This page serves as the definitive source for verified news and press releases related to MIST's innovative arrhythmia treatments, including etripamil nasal spray for PSVT and AFib-RVR management.
Investors and medical professionals will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection provides essential insights into the company's scientific advancements while maintaining compliance with financial disclosure standards.
Key content categories include FDA submission updates, phase 3 trial results analysis, intellectual property developments, and executive leadership announcements. All materials are vetted for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to MIST's latest developments in rapid-onset cardiovascular therapies. Check regularly for updates on groundbreaking treatment models that combine medical innovation with patient empowerment.
Milestone Pharmaceuticals (MIST) reported Q3 2024 financial results and provided updates on CARDAMYST™. The FDA is reviewing the NDA for CARDAMYST in PSVT with a PDUFA date of March 27, 2025. The company's partner Corxel reported positive Phase 3 trial results in China, showing 40.5% of patients converting from PSVT to sinus rhythm versus 15.9% for placebo. Financial highlights include cash position of $76.4M as of September 30, 2024. Q3 net loss was $9.4M, reduced from $15.1M in the prior year period. The company plans to initiate a Phase 3 trial for etripamil in AFib-RVR in H1 2025.
Milestone Pharmaceuticals (Nasdaq: MIST) has announced a virtual investor education event scheduled for October 8, 2024, from 10:00 AM to 11:30 AM ET. Titled 'Learnings from the Field: Expert Perspectives on Managing PSVT and Studying AFib-RVR in the Community Setting', the event will feature cardiologists Dr. Aamer H. Jamali and Dr. Farhad Rafii from Interventional Cardiology Medical Group in West Hills, CA.
The presentation will focus on the impact of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation (AFib) on patients, along with current management practices. It will also highlight clinical trial experiences in PSVT and upcoming trials in atrial fibrillation with rapid ventricular rate (AFib-RVR), which could potentially change the standard of care. A live Q&A session will follow the formal presentation.
Milestone Pharmaceuticals (Nasdaq: MIST) announced positive topline results from a Phase 3 study of etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT) in China, conducted by its licensing partner Ji Xing Pharmaceuticals. The 500-patient trial met its primary endpoint, with 40.5% of etripamil-treated patients converting to sinus rhythm within 30 minutes compared to 15.9% for placebo (p<0.001). Secondary endpoints were also met, and safety data was consistent with previous studies. This expands etripamil's global development to over 2,000 patients. Milestone's partnership with Ji Xing includes potential milestone payments of up to $107.5 million and royalties on future sales in Greater China.
Milestone Pharmaceuticals (Nasdaq: MIST) has appointed Joseph Papa to its Board of Directors, effective September 3, 2024. Papa brings over 35 years of experience in the pharmaceutical and healthcare industry, having served as Chairman and CEO of Bausch + Lomb, Bausch Health, and Perrigo. His expertise includes navigating companies through rapid growth, transformation, and strategic M&A transactions.
Robert J. Wills, Chairman of Milestone's Board, expressed enthusiasm for Papa's addition, citing his track record in driving growth and extensive experience across biopharmaceutical companies. Papa's appointment comes as Milestone prepares for the potential approval of CARDAMYST™ (etripamil nasal spray) for paroxysmal supraventricular tachycardia. Papa expressed excitement about joining Milestone, praising the company's leadership, innovation culture, and commitment to improving lives of people with heart conditions.
Milestone Pharmaceuticals (Nasdaq: MIST) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City from September 9-11, 2024. President and CEO Joe Oliveto will engage in a Fireside Chat on September 10th at 2 PM EDT.
The event will be accessible via webcast, available both live and as a replay for approximately 90 days after the presentation. Interested parties can view the webcast in the News & Events section of Milestone's website at www.milestonepharma.com.
This participation provides an opportunity for Milestone Pharmaceuticals to showcase its latest developments and engage with investors in a prominent global investment forum.
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) announced an upcoming data presentation on etripamil at the ESC Congress 2024 in London on August 30, 2024. Professor John Camm will present patient-reported outcomes data from the NODE-303 Phase 3 trial of etripamil in paroxysmal supraventricular tachycardia (PSVT) in a moderated poster presentation.
The presentation, titled "Quality of Life Measures with Etripamil Self-Administration for Acute Episodes of Paroxysmal Supraventricular Tachycardia in a Medically Unsupervised Setting: Patient-Reported Outcomes from NODE-303," will provide insights about patient experience, satisfaction, and disease management. Dr. David Bharucha, Chief Medical Officer at Milestone Pharmaceuticals, emphasized the importance of this data in understanding the self-administration of investigational etripamil nasal spray in a medically unsupervised setting.
Milestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2024 financial results and provided regulatory updates. Key highlights include:
1. FDA accepted the NDA for CARDAMYST™ (etripamil) nasal spray for PSVT, with a PDUFA date set for March 2025.
2. Cash position of $83.3 million as of June 30, 2024, expected to fund operations into 2026.
3. Planning for Phase 3 trial of etripamil in AFib-RVR, with enrollment expected to start in H1 2025.
4. Q2 2024 net loss of $9.4 million, compared to $16.0 million in Q2 2023.
5. Reduced R&D expenses due to completion of Phase 3 studies.
6. Two new independent directors appointed to the board in July 2024.
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) has announced its participation in the upcoming BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024. The company's President and CEO, Joe Oliveto, will be featured in a Fireside Chat presentation on August 6th at 8 AM EDT.
Investors and interested parties can access the presentation live or as a replay for approximately 90 days after the event. The webcast will be available in the News & Events section of Milestone's corporate website at www.milestonepharma.com. This conference provides an opportunity for Milestone Pharmaceuticals to showcase its latest developments and engage with the investment community in the biotechnology sector.
Milestone Pharmaceuticals (Nasdaq: MIST) has announced a refresh of its Board of Directors. Stuart Duty and Andrew Saik have been appointed as new independent directors, effective immediately. A third independent director will be appointed in the near term. This move comes as part of a Cooperation Agreement with Alta Fundamental Advisers , a shareholder.
Mr. Duty brings over 30 years of experience in investment banking and operations in biotechnology and specialty pharmaceuticals. Mr. Saik has more than 25 years of accounting and finance experience, including CFO roles at several biopharmaceutical companies. The company expects their varied perspectives to provide valuable insights as Milestone approaches an exciting phase.
Debra K. Liebert and Richard C. Pasternak will not seek reelection at the upcoming Annual Meeting. The changes aim to strengthen leadership as Milestone works towards providing new treatment options for patients with paroxysmal supraventricular tachycardia and atrial fibrillation.
Milestone Pharmaceuticals (Nasdaq: MIST) will host Part I of its virtual investor educational series on June 20, 2024, at 8:00 AM ET. The event, titled “Learnings from the Field: Expert Perspectives on Managing PSVT in the Community Setting,” will feature Dr. George Mark and Dr. Vivek Sailam from The Heart House and Cooper University Health Care. They will discuss the impact of paroxysmal supraventricular tachycardia (PSVT) on patients, current treatments, unmet needs, and future treatment expectations. A live Q&A session will follow the presentation.
FAQ
What is the current stock price of Milestone Pharmaceuticals (MIST)?
What is the market cap of Milestone Pharmaceuticals (MIST)?
